


CSHP

PROPOSED RESOLUTION

Introduced by: Ciindy Hesper

Jason Bandy

Paul Sabatini



X 

Jason Bandy

X 

Paul Sabatini

Date: September 29, 2017

Subject: Mandatory Labeling of the Presence of Natural Rubber Latex in Medications

Description of Current Situation:

1. CSHP Professional Policy 2015-04 directs CSHP to adopt ASHP policies and other guidance documents as CSHP Professional policy
2. To adopt as CSHP policy all ASHP Policy Positions, Guidelines, Bulletins and all official Statements in the current edition of the Best Practices for Health-System Pharmacy of the ASHP, except when such policies differ substantially from CSHP policy.
3. To endorse the use of ASHP Position Statements, Guidelines and Technical Assistance Bulletins by its members in their practice settings.
4. CSHP will review all ASHP Policy Positions by 2020 for possible adoption as CSHP Professional Policy.
5. CSHP does not have a policy with respect to latex in medications.
6. The CDC estimates that 1-6% of the general population has latex allergy and specific patient populations are at higher risk
7. ASHP Policy 0501 Mandatory Labeling of the Presence of Latex was adopted in 2005 and reaffirmed in 2014 by the ASHP Council on Pharmacy Practice:

0501

MANDATORY LABELING OF THE PRESENCE OF LATEX

Source: Section of Inpatient Care Practitioners

To urge the Food and Drug Administration to mandate that manufacturers of medications and medication-device combination products include labeling information on whether any component of the product, including its packaging, contains natural rubber latex.

Target:

1. CSHP provides resources to its members, their patients, and the public per the 2017-2021 Strategic Priorities and Goals.
2. CSHP develops professional policy in congruence with other professional organizations, but adopts policy as an independent professional society
3. CSHP provides professional policy that addresses natural rubber latex in medications.

Proposal:

Adopt the following as CSHP Professional Policy:

Mandatory Labeling of the Presence of Latex

To urge the Food and Drug Administration to mandate that manufacturers of medications and medication-device combination products include labeling information on whether any component of the product, including its packaging, contains natural rubber latex.

Rationale:

Patients may be exposed to potentially life-threatening allergens including natural rubber latex in items encountered in the medication-use process (i.e., medications, devices, and supplies). Pharmacy involvement in collection, assessment, and documentation of a complete list of allergens, including natural rubber latex, pertinent to the medication-use process would assist in clinical decision-making. Pharmacists should also minimize patient and healthcare worker exposure to known allergens by limiting or banning the use of latex gloves in pharmacies and striving for latex-safe medication formularies.

Resources Required for Proposed Action(s): Financial: Minimal

CEO time: Minimal

Staff time: Minimal

CSHP Board Action: The Board of Directors reviewed this proposal on October 3, 2017 and recommends approval of this resolution.